US2014057892A1PendingUtilityA1
Prolyl hydroxylase inhibitors and methods of use
Est. expiryJun 26, 2026(expired)· nominal 20-yr term from priority
Inventors:Richard Masaru KawamotoShengde WuArtem G. EvdokimovKenneth D. GreisAngelique Sun BoyerNamal C. Warshakoon
A61P 7/00A61P 7/06A61P 9/10A61P 43/00A61P 31/04A61P 35/00A61P 31/18A61P 27/02A61P 19/02A61P 19/08A61P 17/02A61P 17/06C07D 213/65C07D 405/10C07D 405/04A61K 31/4433C07D 417/04C07C 255/57C07D 401/10C07D 295/192C07D 401/04C07D 213/81C07C 235/60C07C 237/42A61K 31/4418A61P 1/04Y02A50/30
67
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD) heart failure, ischemia, and anemia.
Claims
exact text as granted — not AI-modified1 - 32 . (canceled)
33 . A method for treating a cancer, comprising administering to a patient having a cancer a compound having a structure:
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
R is 3-fluorophenyl;
R 2 is selected from OR 6 and NR 7a R 7b ;
R 6 is selected from hydrogen and methyl; and
R 7a and R 7b are each independently selected from hydrogen, methyl, and ethyl.
34 . The method of claim 3 , wherein the compound is selected from:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
35 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
36 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
37 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
38 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
39 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
40 . The method of claim 33 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
41 . A method for treating anemia associated with chemotherapy, comprising administering to a patient having a anemia associated with chemotherapy a compound having a structure:
or a pharmaceutically acceptable salt, solvate or hydrate thereof, wherein
R is 3-fluorophenyl;
R 2 is selected from OR 6 and NR 7a R 7b ;
R 6 is selected from hydrogen and methyl; and
R 7a and R 7b are each independently selected from hydrogen, methyl, and ethyl.
42 . The method of claim 41 , wherein the compound is selected from:
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
43 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
44 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
45 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
46 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
47 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.
48 . The method of claim 41 , wherein the compound is
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.Join the waitlist — get patent alerts
Track US2014057892A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.